A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy
2005-08-01 Hélène Bruyère, Wilson Yeung, Peter Tsang AffiliationDepartment of Pathology and Laboratory Medicine, Vancouver General Hospital, UBC, Canada, [email protected] and Division of Hematology, Vancouver General Hospital, UBC, Canada
Previous history
Preleukaemia
-
Malignant disease
Breast cancer diagnosed in 2002, treated with radical mastectomy, chemotherapy with cyclophosphamide, epirubicin, 5-fluoro-uracil, radiotherapy.
Inborn condition
-
Clinics case report
Age
61 yrs
Sex
F
Liver
-
Spleen
-
Lymph nodes
-
Cns involv
-
Blood data
Wbc
2.4
Hb
10.7
Platelets
48
Blasts
2
Bone marrow
Neutrophils 0.05 ; Band cells 0.05 ; Metamyelocytes 0.13 ; Myelocytes 0.02 ; Promyelocytes 0.02 ; Blasts 0.51 ; Late normoblasts 0.13 ; Plasma cells 0.01 ; Lymphocytes 0.05 ; Monocytes 0.01 ; Eosinophils 0.02
Cyto path
Cytology
AML-M2
Immunophenotype
Positive for HLA-DR, CD34, CD117, CD13, CD33, MPO, CD56 and CD19 ; Partial Tdt ; Negative for CD7
Precise diagnosis
Hypoplastic AML, therapy related
Survival data
Date diagnosis
04-2005
Treatment
Three cycles of AraC and Danuribicin ; Related bone marrow transplantation planned for September 2005
Complete remission
Yes, 05-2005
Status
A
Date last follow
07-2005
Survival
3 +
Karyotype
Sample
Bone marrow
Culture time
24
Banding
GTG
Results
47,XX,+8,t(16;21)(q24;q22)[13]/46,XX[3]
Images
Partial karyotype showing the t(16;21) and a +8
Comments section
Comments
All of the nine patients whose treatments were reported (3-9), plus the current case, were treated with a combination of alkylating agents and topoisomerase II inhibitors, +/- radiotherapy.
Article Bibliography
| Pubmed ID | Last Year | Title | Authors |
|---|---|---|---|
| 2758395 | 1989 | Cytogenetics of childhood acute nonlymphocytic leukemia. | Raimondi SC et al |
| 7819102 | 1994 | Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies. | Nylund SJ et al |
| 8043877 | 1994 | Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. | Traweek ST et al |
| 8932000 | 1996 | Secondary acute myeloblastic leukemia with t(16;21) (q24;q22). involving the AML1 gene. | Berger R et al |
| 9216714 | 1997 | A recurrent translocation, t(16;21)(q24;q22), associated with acute myelogenous leukemia: identification by fluorescence in situ hybridization. | Shimada M et al |
| 9631585 | 1998 | A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide. | Takeda K et al |
| 10995019 | 2000 | AML1-MTG16 fusion gene in therapy-related acute leukemia with t(16;21)(q24;q22): two new cases. | Salomon-Nguyen F et al |
| 11224496 | 2001 | AML1/MTG16 fusion gene from a t(16;21)(q24;q22) translocation in treatment-induced leukemia after breast cancer. | La Starza R et al |
| 11999578 | 2002 | A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene. | Kondoh K et al |
| 11921272 | 2002 | 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. | Slovak ML et al |
Citation
Hélène Bruyère, Wilson Yeung, Peter Tsang
A new case of t(16;21)(q24;q22) in a secondary AML-M2 following breast cancer therapy
Atlas Genet Cytogenet Oncol Haematol. 2005-08-01
Online version: http://atlasgeneticsoncology.org/case-report/208811/a-new-case-of-t(16
